Abstract
We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT). Although TMZ is generally safe and well-tolerated, she developed a sudden onset of prolonged and severe thrombocytopenia as the most prominent event of pancytopenia during the combined treatment, leading to discontinuation of the combined therapy. Thrombocytopenia lasted for more than 2 months with intensive, intermittent platelet transfusions. A bone marrow aspiration and biopsy performed after recovery of severe suppression still revealed reduced number of megakaryocytes. O 6-methylguanine-DNA methyltransferase (MGMT) analyses showed methylated MGMT promoter in GBM, but unmethylated promoters in both peripheral blood leukocytes and bone marrow cells. This is the first report suggesting the irrelevance of MGMT status of normal hematopoietic cells to TMZ-induced severe thrombocytopenia and pancytopenia.
This is a preview of subscription content, log in via an institution to check access.
References
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331
Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954–5958
Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368–381. doi:10.2353/jmoldx.2007.060167
Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncology 9:47–52. doi:10.1215/15228517-2006-024
Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature. J Neurooncol 85:229–230. doi:10.1007/s11060-007-9403-6
Jalali R, Singh P, Menon H et al (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 85:105–107. doi:10.1007/s11060-007-9398-z
Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438. doi:10.1016/S1470-2045(06)70696-9
Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963
Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296–307. doi:10.1038/nrc1319
Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16:833–839. doi:10.1002/bies.950161110
Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223. doi:10.1016/S0079-6603(08)60879-X
Nagane M, Kobayashi K, Ohnishi A et al (2007) Prognostic significance of O 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 37:897–906. doi:10.1093/jjco/hym132
Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi:10.1056/NEJM200011093431901
George JN, Raskob GE, Shah SR et al (1998) Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129:886–890
Anon (1989) Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Arch Intern Med 149:1036–1040. doi:10.1001/archinte.149.5.1036
Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011. doi:10.1038/sj.bjc.6600827
Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197. doi:10.1200/JCO.2007.14.8163
Acknowledgments
This work was supported partially by grants of the Ministry of Health, Labour, and Welfare of Japan (H17-ganrinsyou-ippan-005 and 17shi-4) (to MN). WA is partially supported by NGFNplus: Brain Tumor Network.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nagane, M., Nozue, K., Shimizu, S. et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma—analysis of O 6-methylguanine-DNA methyltransferase status. J Neurooncol 92, 227–232 (2009). https://doi.org/10.1007/s11060-008-9754-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9754-7